Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : interferon alfa-2b
- other : observation
Phase: Phase 3
Ages Eligible For Study:
- Histologically confirmed primary melanoma of cutaneous origin - Stage II (T3 N0 M0 1.5-4.0 mm Breslow depth) - Clinically negative regional lymph node pathologic status unknown OR - Histologically negative regional lymph nodes - Stage III (T4 N0 M0) - Greater than 4.0 mm Breslow depth OR - Stage III (T1-4 N1) - One lymph node positive microscopically - Patients must meet at least 1 of the following criteria: - T2b N0 - primary melanoma 1.01-2.0 mm with ulceration, node negative - T3a-b N0 - primary melanoma 2.01-4.0 mm with and without ulceration, node negative - T4a-b N0 - primary melanoma > 4.0 mm with or without ulceration, node negative - T1a N1a-2a (microscopic) - primary melanoma of any thickness with microscopically positive lymph node (any number) - Patients with a positive sentinel node should undergo complete lymphadenectomy of the nodal basin prior to study - Must complete all primary therapy (wide excision with or without lymphadenectomy) and be randomized in this study within 84 days of wide excision - Must have undergone an adequate wide excision of the primary lesion - Age 18 and over (For ECOG patients only, patients must be >=10 years) - Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1 - Adequate hematopoietic, hepatic, and renal function based on the following tests: - White blood cell (WBC) cout at least 3,000/mm^3 - Platelet count at least 125,000/mm^3 - Hematocrit at least 30% - Bilirubin no greater than 2 times upper limit of normal (ULN) - Aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase no greater than 2 times ULN - If lactate dehydrogenase or alkaline phosphatase is above normal, a contrast-enhanced computed tomography (CT) scan or Magnetic resonance imaging (MRI) of the liver is required to document the absence of tumor - Blood urea nitrogen (BUN) no greater than 33 mg/dL OR Creatinine no greater than 1.8 mg/dL - No other concurrent or prior malignancies within the past 5 years except: - Cancer in situ - Lobular carcinoma in situ of the breast - Carcinoma in situ of the cervix - Atypical melanocytic hyperplasia or Clark 1 melanoma in situ - Basal or squamous cell skin cancer - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study